PMID- 31888191
OWN - NLM
STAT- MEDLINE
DCOM- 20200504
LR  - 20211204
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 20
IP  - 24
DP  - 2019 Dec 16
TI  - Humanized Mice as an Effective Evaluation System for Peptide Vaccines and Immune 
      Checkpoint Inhibitors.
LID - 10.3390/ijms20246337 [doi]
LID - 6337
AB  - Peptide vaccination was developed for the prevention and therapy of acute and 
      chronic infectious diseases and cancer. However, vaccine development is 
      challenging, because the patient immune system requires the appropriate human 
      leukocyte antigen (HLA) recognition with the peptide. Moreover, antigens 
      sometimes induce a low response, even if the peptide is presented by 
      antigen-presenting cells and T cells recognize it. This is because the patient 
      immunity is dampened or restricted by environmental factors. Even if the immune 
      system responds appropriately, newly-developed immune checkpoint inhibitors 
      (ICIs), which are used to increase the immune response against cancer, make the 
      immune environment more complex. The ICIs may activate T cells, although the 
      ratio of responsive patients is not high. However, the vaccine may induce some 
      immune adverse effects in the presence of ICIs. Therefore, a system is needed to 
      predict such risks. Humanized mouse systems possessing human immune cells have 
      been developed to examine human immunity in vivo. One of the systems which uses 
      transplanted human peripheral blood mononuclear cells (PBMCs) may become a new 
      diagnosis strategy. Various humanized mouse systems are being developed and will 
      become good tools for the prediction of antibody response and immune adverse 
      effects.
FAU - Kametani, Yoshie
AU  - Kametani Y
AD  - Department of Molecular Life Science, Division of Basic Medical Science, Tokai 
      University School of Medicine; 143 Shimokasuya, Isehara-shi, Kanagawa 259-1193, 
      Japan.
AD  - Institute of Advanced Biosciences, Tokai University, 4-1-1 Kitakaname, 
      Hiratsuka-shi, Kanagawa 259-1292, Japan.
FAU - Ohno, Yusuke
AU  - Ohno Y
AD  - Department of Molecular Life Science, Division of Basic Medical Science, Tokai 
      University School of Medicine; 143 Shimokasuya, Isehara-shi, Kanagawa 259-1193, 
      Japan.
FAU - Ohshima, Shino
AU  - Ohshima S
AD  - Department of Molecular Life Science, Division of Basic Medical Science, Tokai 
      University School of Medicine; 143 Shimokasuya, Isehara-shi, Kanagawa 259-1193, 
      Japan.
FAU - Tsuda, Banri
AU  - Tsuda B
AD  - Department of Breast and Endocrine Surgery, Tokai University School of Medicine, 
      143 Shimokasuya, Isehara-shi, Kanagawa 259-1193, Japan.
FAU - Yasuda, Atsushi
AU  - Yasuda A
AD  - Department of Internal Medicine, Division of Nephrology, Endocrinology and 
      Metabolism, Tokai University School of Medicine, 143 Shimokasuya, Isehara-shi, 
      Kanagawa 259-1193, Japan.
FAU - Seki, Toshiro
AU  - Seki T
AD  - Department of Internal Medicine, Division of Nephrology, Endocrinology and 
      Metabolism, Tokai University School of Medicine, 143 Shimokasuya, Isehara-shi, 
      Kanagawa 259-1193, Japan.
FAU - Ito, Ryoji
AU  - Ito R
AUID- ORCID: 0000-0003-2903-2332
AD  - Central Institute for Experimental Animals, 3-25-12 Tonomachi, Kawasaki-ku, 
      Kawasaki-shi, Kanagawa 210-0821, Japan.
FAU - Tokuda, Yutaka
AU  - Tokuda Y
AD  - Department of Breast and Endocrine Surgery, Tokai University School of Medicine, 
      143 Shimokasuya, Isehara-shi, Kanagawa 259-1193, Japan.
LA  - eng
GR  - 22220007/Japan Society for the Promotion of Science/
PT  - Journal Article
PT  - Review
DEP - 20191216
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Vaccines, Subunit)
SB  - IM
MH  - Animals
MH  - Antibody Formation
MH  - Humans
MH  - Immune System/metabolism
MH  - Immunosuppression Therapy
MH  - *Immunotherapy
MH  - Mice
MH  - Models, Animal
MH  - Vaccines, Subunit/*immunology
PMC - PMC6940818
OTO - NOTNLM
OT  - cancer antigen
OT  - humanized mouse
OT  - immune checkpoint inhibitor
OT  - immune suppression
OT  - peptide vaccine
COIS- We have no conflicts of interest.
EDAT- 2020/01/01 06:00
MHDA- 2020/05/06 06:00
PMCR- 2019/12/01
CRDT- 2020/01/01 06:00
PHST- 2019/11/05 00:00 [received]
PHST- 2019/12/06 00:00 [revised]
PHST- 2019/12/12 00:00 [accepted]
PHST- 2020/01/01 06:00 [entrez]
PHST- 2020/01/01 06:00 [pubmed]
PHST- 2020/05/06 06:00 [medline]
PHST- 2019/12/01 00:00 [pmc-release]
AID - ijms20246337 [pii]
AID - ijms-20-06337 [pii]
AID - 10.3390/ijms20246337 [doi]
PST - epublish
SO  - Int J Mol Sci. 2019 Dec 16;20(24):6337. doi: 10.3390/ijms20246337.